Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 18, 2025 | Press Releases

Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia, Pennsylvania–(Newsfile Corp. – September 18, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage...

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025 | Press Releases

Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-7625th cohort patients now being treated in on-going clinical studyKing of Prussia, Pennsylvania–(Newsfile Corp. – September 3, 2025) – Phio...

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025 | Press Releases

Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania–(Newsfile Corp. – August 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025 | Press Releases

King of Prussia, Pennsylvania–(Newsfile Corp. – July 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to...

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025 | Press Releases

Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania–(Newsfile Corp. – July 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...